Business
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
Quarterly EsoGuard® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Quarterly EsoGuard® revenue increased 33 percent sequentially\nExpanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to Medicare coverage\nConference call and webcast to be held tomorrow, March 26th at 8:30 AM ET\nNEW YORK, March 25, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( \"PAVmed\"), today provided a business update for the Company and presented financial results for the year ended December 31, 2023.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast\nThe webcast will take place on March 26, 2024, at 8:30 AM, and be accessible in the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name \"Lucid Diagnostics Business Update\" to join.\nFollowing the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.\nBusiness Update Highlights\n\"We are very pleased with the excellent progress Lucid has made on multiple fronts in the fourth quarter and recent weeks,\" said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. \"We saw solid revenue growth on stable test volume and our revenue cycle management processes are yielding improving allowances and stable pricing. Our #CYFT program targeting firefighters and other groups is thriving and we have a robust pipeline of scheduled high-volume testing events. Most importantly, we have rapidly built our clinical validity and clinical utility evidence base to drive positive medical policy coverage, including what now we believe is line of sight to Medicare coverage. Equipped with sufficient data, we have for the first time engaged with medical directors at major commercial payors to request positive coverage. Our direct contracting initiative is also accelerating and we are excited about the near-term prospects of delivering contracts, testing and revenue.\" \nHighlights from the fourth q...